Comparing two intermittent fasting plans for weight loss in adults with obesity
Tests two intermittent fasting plans against standard weight-loss advice in adults with obesity.
Plain-language title generated from the registry record
Registry title: Longitudinal Monitoring During Intermittent Fasting Protocols in Obese Adults
Key facts
- Where
- Zurich, SwitzerlandSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 50 years old?
Source: NCT06323889, who can take part
Where in Switzerland
- Department of Endocrinology, Diabetology and Clinical NutritionZurich, SwitzerlandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Zurich
- Trial code
- NCT06323889
- Record updated
- 20 December 2024
- Original description
LIMITFOOD2 is a randomized clinical intervention study that investigates the effects of two different intermittent fasting protocols compared to a control group on the health of obese adults. A total of 90 participants will be randomized into three equally sized groups: a modified alternate day fasting, a time-restricted eating and a control group, receiving general weight-loss counseling.Read full original descriptionShow less
Longitudinal Monitoring During Different Intermittent Fasting Protocols in Obese Adults - a Randomized Clinical Trial
LIMITFOOD2 is a randomized clinical intervention study that investigates the effects of two different intermittent fasting protocols compared to a control group on the health of obese adults. A total of 90 participants will be randomized into three equally sized groups: a modified alternate day fasting, a time-restricted eating and a control group, receiving general weight-loss counseling.
Inclusion: Age between 18-50 years, both inclusive; Obese, BMI between 30 and 40 kg/m\^2 (obesity grade I or II), both inclusive; Non-smoker; Good knowledge of German or English language; Stable weight change (change < +/- 3% current bodyweight) for 3 months prior to the study; HbA1c < 6.5% without glucose lowering medication; LDL-cholesterol < 4.6mmol/l without lipid lowering medication.
Exclusion: Antibiotics intake during 3 months prior to the study due to possible interference with metabolic parameters; Known alcohol, substance or drug abuse, concomitant medication; Therapy with antidepressants within the past 6 months; Regular therapy with acetylsalicyclic acid or current medication to regulate blood sugar, blood pressure or lipids; Food intolerances, allergies and sensitivities (severe food allergies) or dietary restrictions (e.g. vegan lifestyle); Diabetes; Acute or chronic infections, malignant disease, renal, hepatic (more than two-fold increased transaminases), pulmonary, neurological (epilepsy) or psychiatric diseases, manifested atherosclerosis, or any other disease precluding participation in the study; Participants who have a fasting period of > 12h per day on a regular basis and do not eat at least three main meals per day; Current habitual use of dietary supplements (e.g., vitamins, minerals) and/or unwillingness to cease intake of dietary supplements; More than four hours of physical exercise per week; Women who are pregnant, breast-feeding or aiming to become pregnant during course of the trial; Women and men on hormonal supplementation; Women with an irregular menstrual cycle according to the FIGO criteria; Participants likely to fail to comply with the study protocol; Participants who do not give informed consent.